Ceryvyn Therapeutics Ltd
Other OTCTotal Valuation
Ceryvyn Therapeutics Ltd carries a market capitalization of 13.68M, placing it among publicly traded companies globally. Its enterprise value stands at 819.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.68M |
| Enterprise Value | 819.31M |
Share Statistics
Ceryvyn Therapeutics Ltd currently has 1.23B shares outstanding.
| Shares Outstanding | 1.23B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Ceryvyn Therapeutics Ltd maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.14 |
| Quick Ratio | 3.05 |
| Debt / Equity | -186.42 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Stock Price Statistics
Ceryvyn Therapeutics Ltd's stock has declined approximately -97.72727% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.72727% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.24 |
| Average Volume (20 Days) | N/A |
Cash Flow
| Operating Cash Flow | N/A |
| Capital Expenditures | -7,006.02 |
| Free Cash Flow | -7,006.02 |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 5.46 |
| FCF Yield | N/A |
Stock Splits
Ceryvyn Therapeutics Ltd's most recent stock split took place on November 14, 2023 with a 50:53 split ratio.
| Last Split Date | 11/14/2023 |
| Split Ratio | 50:53 |
Scores
Ceryvyn Therapeutics Ltd posts an Altman Z-Score of -11.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.13 |